Why Is CORCEPT THERAPEUTICS (CORT) Stock Down Today?

Corcept Therapeutics shares fell 20.13 percent to close at $85.86 on Friday. The sharp decline followed the release of late-stage antibody-conjugate data for ovarian cancer, which disappointed the market despite recent positive guidance in other therapeutic areas.

What Happened

The stock opened at $106.05, a 1.3 percent gap down from the prior close of $107.50. Trading remained volatile throughout the day, with the session high reaching $106.09 at 9:30 AM ET. The selling pressure intensified in the afternoon, driving the price to a session low of $84.13 at 3:15 PM ET. The final print was $85.42. Volume reached 2.2 million shares, which is 1.9 times the three-month daily average.

The primary driver was the release of phase 3 data for the company's antibody-conjugate in ovarian cancer. While the company recently announced that the American Diabetes Association and the European Association for the Study of Diabetes recommended hypercortisolism screening in difficult-to-control type 2 diabetes, citing its CATALYST mifepristone trial, the oncology results weighed on the stock. HC Wainwright & Co. reiterated a Buy rating on the stock and maintained a $165 price target.

What The Data Shows

Corcept Therapeutics has a market capitalization of $12.6 billion and a P/E ratio of 237.0. Revenue grew 16.0 percent over the trailing twelve months, while the net margin stands at 6.6 percent. The stock has a beta of 0.40 and a 52-week range of $28.66 to $126.38. Over the last eight sessions, the stock moved down 12.6 percent from $119.08 to $104.04. On October 23, 2026, the stock printed one fresh 52-week high and 25 fresh 52-week lows.

Insider activity has been notable, with 21 sells totaling $53.9 million in the last 90 days and no buys. Recent sales include Wilson James N, Vieira Roberto Wandenkolk, and Maduck Sean. Congressional trades show one buy and one sell in the last 90 days, with Donald J. Trump selling $1,001 to $15,000 on July 29, 2026, and buying a similar amount on June 15, 2026.

What To Watch

Investors will monitor the broader coverage of the late-stage ovarian cancer data and any subsequent analyst adjustments to price targets following the significant drop in share price.